Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:activities |
long-acting insulin
insulin receptor agonist |
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2015
|
| gptkbp:brand |
gptkb:Tresiba
|
| gptkbp:clinical_trial |
gptkb:Phase_4
gptkb:Type_1_diabetes ongoing Phase 3 Type 2 diabetes basal insulin therapy |
| gptkbp:competitors |
gptkb:Lantus
gptkb:Toujeo gptkb:Levemir |
| gptkbp:contraindication |
severe liver disease
severe kidney disease hypersensitivity to insulin |
| gptkbp:developed_by |
gptkb:Novo_Nordisk
|
| gptkbp:dosage_form |
individualized
|
| gptkbp:duration |
long-acting
|
| gptkbp:education |
carry glucose source
recognize hypoglycemia symptoms monitor blood glucose regularly |
| gptkbp:feedback |
generally positive
improved flexibility better control of blood sugar |
| gptkbp:formulation |
gptkb:software_framework
|
| gptkbp:frequency |
once daily
|
| gptkbp:highest_point |
no peak
|
| https://www.w3.org/2000/01/rdf-schema#label |
Insulin degludec
|
| gptkbp:ingredients |
C256 H383 N65 O77 S
|
| gptkbp:interacts_with |
diuretics
beta-blockers thiazolidinediones |
| gptkbp:is_used_for |
diabetes management
type 2 diabetes type 1 diabetes |
| gptkbp:lifespan |
25 hours
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
over 70 countries
|
| gptkbp:packaging |
vial
pen device |
| gptkbp:pharmacokinetics |
lower blood glucose levels
steady state achieved after 2-3 days |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:premiered_on |
1 hour
|
| gptkbp:provides_information_on |
recommended for Type 1 diabetes
recommended for Type 2 diabetes |
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA TGA |
| gptkbp:research_focus |
patient adherence
improving glycemic control minimizing hypoglycemia risk |
| gptkbp:sales |
increasing
|
| gptkbp:side_effect |
weight gain
injection site reactions hypoglycemia |
| gptkbp:storage |
refrigerated
|
| gptkbp:weight |
3463.9 g/mol
|